How far are we from a cure for CLL?
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
ASH 2015 highlights in multiple myeloma by Prof. Ola Landgren
Update on ELOQUENT-2: Phase 3 trial of elotuzumab in relapsed/refractory multiple myeloma
Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL